150 related articles for article (PubMed ID: 31512001)
21. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
Nakanishi H; Yonezawa A; Matsubara K; Yano I
Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
[TBL] [Abstract][Full Text] [Related]
22. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
24. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake T
Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
[TBL] [Abstract][Full Text] [Related]
25. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
26. Peripheral Hybrid CB
Zawatsky CN; Park JK; Abdalla J; Kunos G; Iyer MR; Cinar R
Front Endocrinol (Lausanne); 2021; 12():744857. PubMed ID: 34650521
[TBL] [Abstract][Full Text] [Related]
27. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
[TBL] [Abstract][Full Text] [Related]
28. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
[TBL] [Abstract][Full Text] [Related]
29. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
30. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells.
Louisa M; Soediro TM; Suyatna FD
Asian Pac J Cancer Prev; 2014; 15(4):1639-42. PubMed ID: 24641381
[TBL] [Abstract][Full Text] [Related]
31. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
Ganguly S; Panetta JC; Roberts JK; Schuetz EG
Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
[TBL] [Abstract][Full Text] [Related]
32. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
33. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Minderman H; O'Loughlin KL; Pendyala L; Baer MR
Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
[TBL] [Abstract][Full Text] [Related]
34. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
35. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
36. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
37. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
40. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.
Pavek P; Merino G; Wagenaar E; Bolscher E; Novotna M; Jonker JW; Schinkel AH
J Pharmacol Exp Ther; 2005 Jan; 312(1):144-52. PubMed ID: 15365089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
